Purpose. To assess the metastatic pattern of the histological subtype myxoid liposarcoma (MLS) with no or few round cells. Methods. Forty-five patients (F/M?=?27/18, mean age 49 (range 17–85) years) were diagnosed with MLS at two Danish sarcoma centres in the period 1995–2004. A retrospective review of patients' files combined with an extraction of survival data from the Danish Centralised Civil Register was performed. Results. Seven patients had distant metastases during the observation period. Two patients had metastases at the time of diagnosis, while metastases occurred within 2.5 years in four patients, and in one patient 11.9 years after primary diagnosis. All metastases occurred at extrapulmonary sites. The first local relapse occurred within 3 years after surgery in six patients, in one patient after 4.0 years, and in one patient 7.7 years after surgery. The 5- and 10-year overall survival was 80% and 69%, respectively. Both the 5- and 10-year distant metastases-free survival was, respectively, 86%. The 5- and 10-year local relapse-free survival was, respectively, 83% and 80%. Conclusions. Patients with MLS had only extra-pulmonary metastases, and no lung metastases were found. Most local relapses and distant metastases occurred within the first 2-3 years after surgery. 1. Introduction Sarcomas are very rare tumours and comprise approximately 1% of all newly diagnosed cancers [1]. The incidence is around 6 per 100,000 and has been rather constant during the last many years [2]. Liposarcomas are the second most frequent type of soft tissue sarcoma (STS), comprising 15–20% of all STS [3], and 30% of all liposarcomas are of the myxoid or myxoid round cell liposarcoma subtype [4, 5]. Originally, the myxoid and round cell liposarcomas (RCLS) were looked upon as two different histological subtypes but are now considered to represent a continuum of the same type, and the occurrence of areas with round cells is well known to be a poor prognostic factor [4]. STS has a tendency to, for most of the histological types, to metastasise haematogenously to the lungs whereas metastases to lymph nodes are uncommon [6]. Therefore, most guidelines recommend X-ray or computed tomography (CT scan) of the chest as the preferred method for evaluation of metastatic disease in the postoperative follow-up period [7–9]. Previously published studies have shown that the metastatic pattern in liposarcoma and especially myxoid liposarcoma (MLS) also includes extrapulmonary sites [10–18]. The purpose of this study was to evaluate the metastatic pattern, local relapse, and
References
[1]
C. D. M. Fletcher, A. Rydholm, S. Singer, M. Sundaram, and J. M. Coindre, “Soft tissue tumours: epidemiology, clinical features, histopathological typing and grading,” in WHO Classification of Tumours. Pathology and Genetics of Soft Tissue and Bone, C. D. M. Fletcher, K. K. Unni, and F. Mertens, Eds., pp. 12–18, IARC Press, Lyon, France, 2002.
[2]
F. Ducimetière, A. Lurkin, D. Ranchère-Vince et al., “Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing,” PLoS ONE, vol. 6, no. 8, article e20294, 2011.
[3]
S. Daugaard, “Current soft-tissue sarcoma classifications,” European Journal of Cancer, vol. 40, no. 4, pp. 543–548, 2004.
[4]
C. Antonescu and M. Ladanyi, “Myxoid liposarcomaeds,” in World Health Organisation of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, C. D. M. Fletcher, K. K. Unni, and F. Mertens, Eds., pp. 40–43, IARC Press, Lyon, France, 2002.
[5]
K. Engstr?m, “Clinical and molecular studies of liposarcoma,” Acta Orthopaedica, vol. 80, supplement 334, pp. 24–30, 2009.
[6]
K. M. Skubitz and D. R. D'Adamo, “Sarcoma,” Mayo Clinic Proceedings, vol. 82, no. 11, pp. 1409–1432, 2007.
[7]
P. G. Casali and J.-Y. Blay, “Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, no. 5, pp. v198–v203, 2010.
[8]
R. Grimer, I. Judson, D. Peake, and B. Seddon, “Guidelines for the management of soft tissue sarcomas,” Sarcoma, vol. 2010, Article ID 506182, 2010.
[9]
S. Sinha and A. H. S. Peach, “Diagnosis and management of soft tissue sarcoma,” BMJ, vol. 341, article c7170, 2010.
[10]
M. Fiore, F. Grosso, S. Lo Vullo et al., “Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution,” Cancer, vol. 109, no. 12, pp. 2522–2531, 2007.
[11]
D. B. Pearlstone, P. W. Pisters, R. J. Bold et al., “Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up,” Cancer, vol. 85, pp. 85–92, 1999.
[12]
S. H. Estourgie, G. P. Nielsen, and M. J. Ott, “Metastatic patterns of extremity myxoid liposarcoma and their outcome,” Journal of Surgical Oncology, vol. 80, no. 2, pp. 89–93, 2002.
[13]
A. J. Spillane, C. Fisher, and J. M. Thomas, “Myxoid liposarcoma—the frequency and the natural history of nonpulmonary soft tissue metastases,” Annals of Surgical Oncology, vol. 6, no. 4, pp. 389–394, 1999.
[14]
B. A. Guadagnolo, G. K. Zagars, M. T. Ballo et al., “Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 3, pp. 760–765, 2008.
[15]
S. E. ten Heuvel, H. J. Hoekstra, R. J. van Ginkel, E. Bastiaannet, and A. J. H. Suurmeijer, “Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up,” Annals of Surgical Oncology, vol. 14, no. 1, pp. 222–229, 2007.
[16]
J. Haniball, V. P. Sumathi, L.-G. Kindblom et al., “Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma,” Sarcoma, vol. 2011, Article ID 538085, 2011.
[17]
N. Asano, M. Susa, S. Hosaka et al., “Metastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experience,” Sarcoma, vol. 2012, Article ID 345161, 2012.
[18]
Y. Nishida, S. Tsukushi, H. Nakashima, and N. Ishiguro, “Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall,” Clinical Orthopaedics and Related Research, vol. 468, no. 11, pp. 3041–3046, 2010.
[19]
W. F. Enneking, S. S. Spanier, and M. Goodman, “A system for the surgical staging of musculoskeletal sarcoma,” Clinical Orthopaedics and Related Research, vol. 153, pp. 106–120, 1980.
[20]
K. Sheah, H. A. Ouellette, M. Torriani, G. P. Nielsen, S. Kattapuram, and M. A. Bredella, “Metastatic myxoid liposarcomas: imaging and histopathologic findings,” Skeletal Radiology, vol. 37, no. 3, pp. 251–258, 2008.
[21]
C. S. Trovik, “Local recurrence of soft tissue sarcoma: a Scandinavian sarcoma group project,” Acta Orthopaedica Scandinavica, vol. 72, supplement 300, pp. 1–31, 2001.